To evaluate the feasibility of a standardized protocol for acquisition and analysis of dynamic contrast material-enhanced (DCE) and dynamic susceptibility contrast (DSC) magnetic resonance (MR) imaging in a multicenter clinical setting and to verify its accuracy in predicting glioma grade according to the new World Health Organization 2016 classification.
The local research ethics committees of all centers approved the study, and informed consent was obtained from patients. One hundred patients with glioma were prospectively examined at 3.0 T in seven centers that performed the same preoperative MR imaging protocol, including DCE and DSC sequences. Two independent readers identified the perfusion hotspots on maps of volume transfer constant (K trans ), plasma (v p ) and extravascular-extracellular space (v e ) volumes, initial area under the concentration curve, and relative cerebral blood volume (rCBV). Differences in parameters between grades and molecular subtypes were assessed by using Kruskal-Wallis and Mann-Whitney U tests. Diagnostic accuracy was evaluated by using receiver operating characteristic curve analysis.
Results:
The whole protocol was tolerated in all patients. Perfusion maps were successfully obtained in 94 patients. An excellent interreader reproducibility of DSC-and DCE-derived measures was found. Among DCE-derived parameters, v p and v e had the highest accuracy (are under the receiver operating characteristic curve [A z ] = 0.847 and 0.853) for glioma grading. DSC-derived rCBV had the highest accuracy (A z = 0.894), but the difference was not statistically significant (P . .05). Among lower-grade gliomas, a moderate increase in both v p and rCBV was evident in isocitrate dehydrogenase wild-type tumors, although this was not significant (P . .05).
Conclusion:
A standardized multicenter acquisition and analysis protocol of DCE and DSC MR imaging is feasible and highly reproducible. Both techniques showed a comparable, high diagnostic accuracy for grading gliomas.
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to assess the accuracy of quantitative metrics derived from these techniques in predicting glioma grade, alone or in combination. A secondary aim was to explore the correlation of these metrics with common molecular alterations identified in the new 2016 World Health Organization (WHO) classification of gliomas (20) .
Materials and Methods

Patients
The local research ethics committees of all centers approved the study, and all patients provided signed informed consent prior to MR imaging. From June 2012 to June 2015, 100 consecutive adult patients (mean age, MR imaging has been published (6) . Nonetheless, the low reproducibility among different softwares still remains an open issue (7) (8) (9) .
Dynamic contrast material-enhanced (DCE) MR imaging has been recently introduced in the preoperative assessment and follow-up of brain tumors. The DCE signal intensitytime curve reflects a combination of tissue perfusion, microvessel permeability, and extravascular-extracellular space (5, 10) , thus allowing for a multiparametric characterization of tumor microvasculature. The advantages of DCE over DSC are fewer susceptibility artifacts and the quantification of blood-brain barrier (BBB) integrity; indeed, the main interest for DCEderived metrics was initially focused on the volume transfer constant (K trans ), a permeability marker correlating with BBB disruption (10) and malignancy (11, 12) . By introducing two-compartment pharmacokinetic models to fit DCE data, the plasma volume or fractional volume of the intravascular compartment (v p ) was also evaluated for glioma grading as a marker for tumor neoangiogenesis (13, 14) , and the fractional volume of the extravascular-extracellular space (v e ) was evaluated as a potential correlate of mitotic activity (15) . The advantage of DSC over DCE is better temporal resolution, allowing better estimation of blood volume. Thus, each technique has strengths that may be valuable in glioma grading.
To date, a number of single-center studies reported a similar accuracy of DSC and DCE in glioma grading (16) (17) (18) (19) , mostly focused on DCE-derived K trans . Nonetheless, a comprehensive evaluation of the accuracy of all DCEderived metrics is still not available in the literature, and, consequently, the value of using either marker or the combination is not clear. Moreover, standardization of DCE acquisition and postprocessing protocols in a multicenter setting is still lacking.
This study aimed to evaluate a standardized protocol for acquisition and analysis of DSC and DCE data in a multicenter clinical setting and 
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P erfusion magnetic resonance (MR) imaging techniques are widely used in the clinical work-up of brain tumors because of their ability to help quantify tumor microvessel proliferation and permeability and thus to measure changes associated with neoangiogenesis, which correlate with tumor malignancy. In particular, dynamic susceptibility contrast (DSC) MR imaging (1) has been extensively explored for glioma grading (2), for prognostic assessment (3), and for differentiating between recurrent tumor and posttreatment changes (4) . However, the lack of acquisition and analysis standardization of DSC has partly limited its inclusion in protocol guidelines for brain tumor diagnosis (5) . Recently, a white paper on consensus recommendations for clinical performance of DSC NEURORADIOLOGY: Standardized Assessment of DCE and DSC MR Images of Brain Glioma Anzalone et al in nordicICE. A semiautomatic arterial vascular input function was obtained in the middle cerebral arteries. Contrast agent leakage correction for the CBV was performed by using the first bolus injection and linear fitting to estimate the T1 contamination by contrast maerial extravasation (22) . DCE-and DSCderived parametric maps were coregistered to the anatomic data sets by using a rigid transformation. The two independent readers drew four ROIs of 25-30 mm 2 on the DSC and DCE postprocessed images based on visual inspection, taking care to avoid normal vessels. Of the four ROIs, the ROI with the highest mean value was then used as the ROI for that image (hotspot). The highest CBV was divided by the CBV in a reference ROI in the contralateral normal-appearing white matter of the centrum semiovale to compute relative CBV (rCBV).
Statistical Analysis
Statistical analysis was performed by using Graph Pad Prism 6 (Graph Pad, San Diego, Calif), SPSS 20.0 for MacOSX (SPSS, IBM, Chicago, Ill) and MedCalc software, version 16.4.2 (MedCalc, Ostend, Belgium). P < .05 was considered to indicate a statistically significant difference. Interreader reproducibility of the DCE-and DSC-derived measures was assessed by using intraclass correlation coefficients. A required sample size of 92 was calculated on the basis of the probability of erroneously concluding accuracy of more than 74% at 10% (one-sided a = .096) and the probability of correctly concluding this proportion was 80% or more at 90% (b = 0.091). Assuming a 10% dropout rate, we attempted to enroll approximately 100 patients.
Because of the nonnormal dis tribution of the variables, nonparametric statistics were used. The KruskalWallis and Dunn multiple pairwise comparison tests were used to assess group differences in perfusion parameters between the three WHO grades (II, III, and IV). The Mann-Whitney U test was used to assess group differences in perfusion parameters between lower-grade gliomas and glioblastomas (II or III vs IV) and among lower-grade
MR Imaging Protocol
A standardized MR imaging protocol including DSC and DCE acquisitions was implemented across the seven centers by using a previously described study design (16, 17) and adapting the parameters to the different MR equipment (Table 1) .
A fixed dose of 10 mL of gadobutrol (Gadovist, 1 mmol/mL; Bayer Healthcare, Berlin, Germany) was administered, divided into two equal parts of 5 mL. The first bolus was injected 50 seconds after the start of DCE acquisition, at a rate of 2 mL/ sec. The second bolus was injected 16 seconds after the start of DSC acquisition, at a rate of 5 mL/sec. Each bolus was followed by a 20-mL saline flush. Thus, the first bolus during DCE presaturated the tissue to reduce the T1 contamination for the following DSC MR imaging study.
MR Imaging Data Analysis
All MR imaging studies were centralized after anonymization and processed by using the nordicICE software package (NordicNeuroLab, Bergen, Norway). Two board-certified neuroradiologists (N.A. and A. Castellano, with 20 and 10 years of experience, respectively), both blinded to histopathologic findings, independently evaluated all MR imaging studies and performed DSC and DCE analysis.
For DCE, patient-specific baseline T1 maps were derived from variable flip angle sequences (three flip angles: 5°, 10°, and 15°) by using the "T1 relaxation analysis" module of nordicICE. Deconvolution with a vascular input function (VIF) was performed by positioning a region of interest (ROI) for VIF selection in the superior sagittal sinus at the level of the lateral ventricles. The maps of v p , K trans , v e , and initial area under the concentration curve (iAUC) were calculated by using the two-compartment extended Tofts model (10, 21) .
For DSC, cerebral blood volume (CBV) maps were calculated by using an established tracer kinetic model applied to the first-pass data, as implemented 52 years; range, 20-80 years; 62 men, 38 women) with a newly detected brain lesion suggestive of glioma at a previous computed tomographic (CT) or MR imaging examination were prospectively recruited in seven Italian centers (Ospedale San Raffaele, Milan; Ospedale Maggiore Policlinico, Milan; Istituto Neurologico Carlo Besta, Milan; Istituto Neurologico Mondino, Pavia; Humanitas Clinical and Research Hospital, Milan; Neuromed, Pozzilli; and ITAB, Chieti). All centers had a 3.0-T MR system and an 8-or 32-channel head coil: four Achieva imagers (Philips Healthcare, Best, the Netherlands), two Magnetom (Verio and Skyra) imagers (Siemens Healthcare, Erlangen, Germany), and one Signa HDxt system (GE Healthcare, Milwaukee, Wis). Bayer Healthcare (Berlin, Germany) gave financial support for running the study; the authors had complete control and property of the study data and of all the information submitted for publication.
Results in 20 of the 100 patients have been previously reported in a prior single-center study (16) . However, the results did not influence this study, as here we report on the application of the standardized DSC and DCE protocol in a multicenter clinical setting.
Exclusion criteria were the presence of severe renal failure, a known allergy to gadolinium-based contrast agents, and corticosteroid administration in the week before the MR imaging study.
All patients underwent preoperative MR imaging that included conventional sequences and DSC and DCE imaging within 2 weeks before surgical resection or biopsy at the neurosurgical department of each participating center, where experienced neuropathologists provided the histopathologic diagnosis according to the WHO 2016 classification (20) .
In 67 of the total cohort of patients, an integrated molecular analysis was provided, including immunohistochemistry and DNA sequencing to detect isocitrate dehydrogenase (IDH) mutations and fluorescence in situ hybridization to detect 1p/19q codeletion.
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Results
A total of 100 patients met the outlined inclusion and exclusion criteria and were recruited to this study. the analysis: Five patients because of inadequate DCE vascular input function deconvolution curves and one because of important susceptibility artifacts on DSC images that hampered appropriate ROI positioning (Fig 1) , v e , and iAUC had the highest A z (0.903). Combining DCE-and DSC-derived parameters slightly improved the accuracy (Fig 3b and Table E3 [online]), but the differences were not statistically significant (P . .05).
Table E4 (online) shows the results of ROC analysis for differentiating WHO II from WHO III glioma and WHO III glioma from glioblastoma. For DCEderived parameters, the A z values for distinguishing grade II from grade III gliomas were generally higher, while for DSC-derived rCBV, the A z for differentiating grade III gliomas from glioblastomas was the highest. However, none of the parameters fulfilled the selection criteria for cutoff value calculation as reported in the Statistical Analysis section. glioblastomas in terms of median values for v p (P = .0227), v e (P = .0270), iAUC (P = .050), and rCBV (P = .0045). The median K trans values were not significantly different (P = .0681).
Each perfusion parameter had a highly significant positive correlation with respect to glioma grade, with r coefficients of 0.663 for v p , 0.669 for K trans , 0.708 for v e , 0.683 for iAUC, and 0.737 for rCBV (P , .0001). The Spearman rank correlation test revealed significant relationships between intrapatient v p and rCBV values (r = 0.765, P , .0001). Table 3 shows A z values, proportional to diagnostic accuracy, and the respective cutoff values of each DCEand DSC-derived parameter for distinguishing lower-grade glioma (WHO II or III) from glioblastoma (WHO IV), according to the new WHO 2016 classification scheme. Among DCEderived parameters, the v p and v e had the highest A z (0.847 and 0.853, respectively). Cutoff values of of 3.06 mL/100 g for v p , 0.122 for iAUC, 0.045 min 21 for K trans , and 16.23% for v e were all associated with a sensitivity of 85.7% and an increasing specificity of 70.8%, 74.5%, 76.5%, and 78.4%, respectively (Table 3) . For DSC, rCBV glioma (30%; WHO II), 23 patients had an anaplastic glioma (25%; WHO III), and 43 patients had a glioblastoma (45%; WHO IV). (Table E1 [online]).
Accuracy of DCE-and DSC-derived Parameters for Distinguishing Glioma Grades
Interreader Reproducibility DSC-and DCE-derived measures had excellent interreader reproducibility, with intraclass correlation coefficients of 0.846 for v p , 0.866 for K trans , 0.782 for v e , 0.873 for iAUC, and 0.858 for rCBV (P , .0001) ( Table E2 [online]). Both readers agreed that ROI positioning was easier at qualitative assessment of DCE-derived maps than of CBV maps, especially in the evaluation of cortical tumors, mainly because of the easier discrimination of large vessels from true intralesional hotspots.
DCE-and DSC-derived Measures according to Glioma Grade
Median values of each hotspot parameter were significantly different between lower-grade gliomas (WHO II or III) and glioblastoma (WHO IV) (P , .0001) ( Table 2 and Fig 2) .
The median value of grade II and grade III gliomas was statistically different for DCE-derived v p (P = .0189), K trans (P = .0037), v e (P = .0037), and iAUC (P = .0037) and for DSC-derived rCBV (P = .0189). Similarly, there was a statistically significant difference between grade III gliomas and * P , .05 indicates a significant difference between groups. P values were adjusted for multiple testing by using the Benjamini-Hochberg correction; original, raw P values are in parentheses. † Calculated by using Kruskal-Wallis and Dunn tests for multiple pairwise comparisons.
‡ Calculated by using Mann-Whitney U test. , and WHO IV (squares) gliomas, and the Mann-Whitney U test was used to assess group differences in median values between lower-grade glioma ( WHO II and III) (stripes) and glioblastoma (squares). * 5 P  .05, * * 5 P  .01, * * * 5 P  .001, * * * * 5 P  .0001. DCE = dynamic contrast-enhanced, DSC = dynamic susceptibility contrast, K trans = volume transfer constant, rCBV = cerebral blood volume, v e = fractional volume of the extravascular-extracellular space, v p = fractional volume of the intravascular compartment, WHO = World Health Organization. 
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DSC-and DCE-derived Markers according to MR Imaging Equipment
Among the examinations in 94 patients included in the final analysis, 65 were performed with a Philips Achieva MR imaging unit, 19 with a Siemens Magnetom, and 10 with a GE Signa HDxt. No difference in DSC-and characterization, 30 were IDH wild-type (97%) ( Table E1 [online]). Among lower-grade gliomas (WHO II or III), the median values of each hotspot parameter did not reach a significant difference between IDH-mutated and IDH wild-type tumors, although both v p and rCBV tended to be higher in the latter (Table 4) . No significant differences in DCE-or DSC-derived perfusion parameters were found between IDH-mutant DCE-and DSC-derived Markers according to Molecular Subtypes Molecular markers used in the 2016 WHO classification were available for 67 of 94 patients. In these patients, 36% (13 of 36) of the lower-grade II and III gliomas were IDH mutant and 1p/19q codeleted, 39% (14 of 36) were IDH mutant without 1p/19q codeletion, and 25% (nine of 36) were IDH wild-type. Of the 31 glioblastomas with molecular Particularly for lower-grade gliomas, it is well established that gene expression can significantly affect the disease course, with IDH-mutant tumors having a better prognosis than wild-type (24) . Of note, in our study no significant differences in DCE-or DSC-derived parameters were found between IDHmutant and IDH-wild-type lower-grade gliomas, although a moderate increase in both v p and rCBV was evident in the latter. Furthermore, no significant differences were found between IDH-mutant tumors with and those without 1p19q codeletion. This may mean that a single imaging parameter is not able to capture the biologic complexity underlying molecular phenotypes in gliomas (25) , which will need to be unraveled by multivariate radiogenomic analyses in the future (26, 27) . Overall, our findings suggest that DCE and DSC techniques may be used independently by performing in an equivalent manner in the preoperative grading of gliomas. Thus, besides the aforementioned scarce sensitivity to susceptibility artifacts of DCE and its multifaceted quantitative evaluation of tumor vasculature, our data further promote the implementation of this technique in the clinical work-up of brain tumors as a possible valid and robust alternative to DSC. In addition, as the value of DCE has been recently highlighted in the follow-up of treated gliomas (4, (28) (29) (30) (31) , it is of utmost importance to obtain robust baseline data as a reference (32) .
This study had limitations. In particular, some issues still remain open regarding the quantification of perfusion parameters. We performed T1 mapping for voxelwise quantification of tumor tissue T1 values; although this is still debated, the strong acquisition and analysis reproducibility of our protocol fosters future implementation in its current form in the clinics.
Because this multicenter study was designed to show reproducibility in grading gliomas was found according to the former WHO classification scheme, which distinguishes low-grade (WHO II) from higher-grade (WHO III or IV) gliomas (Table 3) , confirming the results of previous single-center studies, focused on selected parameters such as rCBV, K trans , and v p (16, 17, 23) . Indeed, we found an rCBV cutoff value of 3.33 for grading gliomas according to this former classification, providing a sensitivity of 86.4% and a specificity of 85.7% (Table 3) , which is in line with results of previous studies considering similar higher values of specificity (2) . As expected, this cutoff is lower than the value of 6.71, referring to the differentiation between lower-grade gliomas and glioblastomas, according to the new 2016 WHO classification scheme.
Regarding the underlying biologic meaning of each parameter, our finding of a better accuracy of v e in differentiating lower-grade gliomas from glioblastoma (Table 3 ) may reflect the higher mitotic activity of the latter, which is typical of more proliferative tumors (15) . Moreover, v e showed the highest accuracy in differentiating grade II from grade III gliomas (Table E2 [online]), and it was also associated with a better performance of K trans over v p and rCBV. These data could be related to lower neoangiogenesis in these tumors and to the presence of anomalous leaky vessels in enhancing grade III tumors, which represented the majority of our cases. In addition, the best performance in differentiating grade III gliomas from glioblastomas was shown by v p and rCBV, probably related to an increase in microvascular density at least in part independent from vessel permeability as measured by K trans (16) . The combination of all DCEderived markers with rCBV did not significantly improve the diagnostic accuracy for grading gliomas, outperforming the single DCE parameters alone but not rCBV significantly (Fig 3  and Table E3 [online]).
A secondary aim of our study was to explore the correlation of DSC-and DCE-derived metrics with important DCE-derived median values was found between these groups according to tumor grade.
Discussion
In this study, we demonstrated the feasibility of a standardized protocol for acquisition and analysis of DSC and DCE MR imaging data in a multicenter clinical setting, with high reproducibility across different imaging MR equipment. The whole protocol was tolerated in all the recruited patients, and only a small number of patients were excluded from the analysis for technical reasons. Moreover, excellent interreader reproducibility of DSC-and DCE-derived measures was reported, further demonstrating the robustness of these techniques in the quantitative assessment of brain gliomas.
Large multicenter studies that correlate imaging findings with the new WHO 2016 brain tumor classification scheme (20) have still not been emphasized in the literature. According to this classification, a high diagnostic accuracy of DCE-and DSC-derived biomarkers in distinguishing lower-grade glioma (WHO II or III) from glioblastoma (WHO IV) was found in this multicenter series of patients (Table 3) . Interestingly, although v p , v e , and rCBV had the highest A z (0.847, 0.853, and 0.894, respectively), their behavior in terms of quantitative evaluation was similar with respect to WHO grade. Nonetheless, it is worth noting that both readers reported easier qualitative evaluation of DCE-derived v p maps than CBV maps for ROI positioning, probably because of the presence of susceptibility artifacts often found on CBV maps in the proximity of large vessels, making the selection of reliable intralesional hotspots difficult, especially in cortical tumors. A significant correlation between the two intravascular compartment markers, v p and rCBV, was also found in this study, thus confirming the potential role of this DCE-derived estimate of tumor neoangiogenesis in glioma grading (16, 17) .
A similar, high diagnostic accuracy of DCE-and DSC-derived parameters of acquisition and analysis and accuracy of DCE and DSC in grading gliomas according to the previous WHO classification, the initial sample size was calculated on the recruitment of 60 patients with WHO III or IV gliomas and 40 patients with WHO II gliomas. As a consequence, a possible limitation was the relative class imbalance in highgrade gliomas with a small number of WHO III cases that does not allow us to draw definitive conclusions on the differentiation of this subgroup from glioblastoma and low-grade gliomas.
Finally, because corticosteroids can affect BBB permeability, our results might not be fully generalizable to patients who have already been treated with steroids (33-35).
In summary, a standardized, multicenter acquisition and analysis protocol of DCE and DSC data is feasible and highly reproducible, with both showing a comparable high diagnostic accuracy in glioma grading according to the new WHO 2016 classification scheme.
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